Bisphosphonate-related osteonecrosis: Genetic and acquired risk factors

Oral Diseases

Volumn 15, Issue 6, 2009, Pages 382-387

  Sarasquete, M E ^a   Gonzalez M ^a,b   San Miguel, J F ^a,b,c   Garcia Sanz R ^a,b,c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c Grupo Español de Mieloma GEM PETHEMA   (Spain)

Author keywords

Bisphosphonates; Genetic risk factors; Osteonecrosis of the jaw

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2C8; ETIDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

AGING; BONE DISEASE; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENETIC VARIABILITY; HEREDITY; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOOTH INJURY;

ARYL HYDROCARBON HYDROXYLASES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; JAW DISEASES; MULTIPLE MYELOMA; OSTEONECROSIS; RISK FACTORS;

EID: 68949219104     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2009.01568.x     Document Type: Review

References (64)

1. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoOaMS (2007). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65: 369 376.
2. von Ahsen N, Oellerich M (2004). The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 103: 586 593.
3. Badros A, Weikel D, Salama A et al (2006). Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945 952.
4. Badros A, Terpos E, Katodritou E et al (2008). Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26: 5904 5909.
5. Bagan JV, Jimenez Y, Murillo J et al (2006). Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42: 327 329.
6. Bagan J, Scully C, Sabater V, Jimenez Y (2009). Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol [Epub ahead of print].
7. Bamias A, Kastritis E, Bamia C et al (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580 8587.
8. Belch AR, Bergsagel DE, Wilson K et al (1991). Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9: 1397 1402.
9. Berenson JR, Lichtenstein A, Porter L et al (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488 493.
10. Berenson JR, Lichtenstein A, Porter L et al (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16: 593 602.
11. Berenson JR, Hillner BE, Kyle RA et al (2002). American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20: 3719 3736.
12. Berenson JR, Rajdev L, Broder M (2006). Treatment strategies for skeletal complications of cancer. Cancer Biol Ther 5: 1074 1077.
13. Bertoldo F, Santini D, Lo CV (2007). Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4: 711 721.
14. Bilezikian JP (2006). Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 355: 2278 2281.
15. Capdevila JH, Falck JR, Harris RC (2000). Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163 181.
16. Clemens MR, Fessele K, Heim ME (1993). Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 66: 141 146.
17. Coxon FP, Rogers MJ (2003). The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int 72: 80 84.
18. De Gobbi M, Viprakasit V, Hughes JR et al (2006). A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 312: 1215 1217.
19. Delmas PD, Charhon S, Chapuy MC et al (1982). Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 4: 163 168.
20. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006). Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91: 968 971.
21. Dimopoulos MA, Kastritis E, Bamia C et al (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20: 117 120.
22. Durie BG, Katz M, Crowley J (2005). Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: 99 102.
23. Edwards BJ, Gounder M, McKoy JM et al (2008). Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9: 1166 1172.
24. Esteve FR, Roodman GD (2007). Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol 20: 613 624.
25. Fleming I (2007). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82: 60 67.
26. Hichiya H, Tanaka-Kagawa T, Soyama A et al (2005). Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 33: 630 636.
27. Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K (2007). Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol 21: 379 386.
28. Hirschhorn JN, Daly MJ (2005). Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6: 95 108.
29. Hoff AO, Toth BB, Altundag K et al (2008). Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826 836.
30. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496 526.
31. Khosla S, Burr D, Cauley J et al (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479 1491.
32. Kyle RA, Yee GC, Somerfield MR et al (2007). American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464 2472.
33. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992). Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340: 1049 1052.
34. Lahuerta JJ, Mateos MV, Martinez-Lopez J et al (2008). Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26: 5775 5782.
35. Landesberg R, Cozin M, Cremers S et al (2008). Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839 847.
36. Lehrer S, Montazem A, Ramanathan L et al (2009). Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67: 159 161.
37. Li SC, Tang P, Lin WC (2007). Intronic microRNA: discovery and biological implications. DNA Cell Biol 26: 195 207.
38. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581 589.
39. Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115 1117.
40. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567 1575.
41. Masarachia P, Weinreb M, Balena R, Rodan GA (1996). Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281 290.
42. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA (1998). A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100: 317 325.
43. Mehrotra B, Ruggiero S (2006). Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 1: 356 360, 515.
44. Merlini G, Parrinello GA, Piccinini L et al (1990). Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 8: 23 30.
45. Pozzi S, Marcheselli R, Sacchi S et al (2007). Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 48: 56 64.
46. Raje N, Woo SB, Hande K et al (2008). Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14: 2387 2395.
47. Rosen LS, Gordon D, Kaminski M et al (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377 387.
48. Rosen LS, Gordon D, Kaminski M et al (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98: 1735 1744.
49. Ruggiero SL, Drew SJ (2007). Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86: 1013 1021.
50. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004). Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527 534.
51. Ruggiero SL, Fantasia J, Carlson E (2006). Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 433 441.
52. Russell RG, Xia Z, Dunford JE et al (2007). Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117: 209 257.
53. Santini D, Vincenzi B, Dicuonzo G et al (2003). Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893 2897.
54. Sarasquete ME, Garcia-Sanz R, Marin L et al (2008). Bisphosphonate- related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112: 2709 2712.
55. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009). Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144: 667 676.
56. Schwartz HC (1982). Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4: 251 253.
57. Stewart AF (2005). Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352: 373 379.
58. Terpos E, Sezer O, Croucher P et al (2009). The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (in press).
59. Viccica G, Vignali E, Marcocci C (2007). Role of the cholesterol biosynthetic pathway in osteoblastic differentiation. J Endocrinol Invest 30: 8 12.
60. Wang J, Goodger NM, Pogrel MA (2003). Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61: 1104 1107.
61. Wessel JH, Dodson TB, Zavras AI (2008). Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66: 625 631.
62. Wood J, Bonjean K, Ruetz S et al (2002). Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055 1061.
63. Zervas K, Verrou E, Teleioudis Z et al (2006). Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134: 620 623.
64. Zhang FL, Casey PJ (1996). Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241 269.